DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

Research & Reports

Searching in Biopharma (1956)

Heart Failure | Current Treatment | Detailed, Expanded Analysis: Patient Journey: EHR and Claims Data Analysis (US)

Heart Failure | Current Treatment | Detailed, Expanded Analysis: Patient Journey: EHR and Claims Data Analysis (US)

Thank you!

Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.

A comprehensive, quantitative understanding of patient progression through all stages of disease management and treatment is critical in both assessing a market opportunity within a therapeutic area and developing a product positioning strategy. DRG’s Patient Journey: EHR and Claims Data Analysis combines analytics with therapy expert insights to illuminate the patients’ path from disease presentation through diagnosis and treatment, highlighting their demographic and clinical features and intersections with key healthcare stakeholders. The patient journey analysis provides a granular roadmap for developers, quantifying key patient segments and identifying intervention points along the disease management continuum to support business decisions spanning opportunity assessment and all drug development stages.

Table of contents

  • Detailed, Expanded Analysis: Patient Journey: EHR and Claims Data Analysis (US)
    • Patient Journey - Chronic Heart Failure - 2019 - US

Already a Client? Log in to access this report.

  • Pub Date: April 2019
  • Author(s): Melissa Curran; Conor Walsh; Graeme Green, PhD, MSc
  • Melissa Curran is a Principal Analyst in the Solution Development group at Decision Resources Group. She has experience conducting opportunity assessments, competitive intelligence, forecasting and primary market research with physicians and payers across a diverse range of therapeutic areas from her previous tenure in both the Consulting and Immune and Inflammatory groups at DRG. Melissa received her BA in biology and minor in business from Providence College.

  • Conor Walsh, , is a Senior Director on the Cardiovascular, Metabolic, and Renal Disorders team at Decision Resources. Prior to joining Decision Resources, he worked at Medical Marketing Research International. Dr. Walsh holds an in bioinformatics and a in cardiac structural biology, both from the University of Manchester. For his doctoral work, he studied the molecular mechanisms underlying heart failure. Dr. Walsh earned his in biotechnology with first class honors from the National University of Ireland in Galway.

  • Graeme Green, , is a director of Decision Resources Group's Cardiovascular, Metabolic and Renal team, where he is focused on the group’s hematology and cardiovascular coverage. He also leads the team’s commercial and therapeutic landscape ; Dr. Green joined DRG in 2007 as a cardiovascular analyst and has authored insight reports covering market dynamics and drug development. Dr. Green holds a in molecular medical microbiology from King’s College London, he also holds an in forensic science and a in biomedical sciences, both also from King’s College. Prior to joining DRG Dr. Green worked for a financial management consultancy.

Purchase Report

Recent reports:
You may also be interested in: